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CCM2 MOLECULAR SIGNALING PATHWAY
Arianne Boylan , Gamze Tanriover, Dana Shin, and Murat Gunel. Department of Neurosurgery, Yale
University, School of Medicine, New Haven , CT.

Cerebral cavernous malformations (CCM) are a central nervous system vascular malformation
often responsible for hemorrhagic strokes. Molecular genetic studies have identified three genes
(CCM1 KRIT1, CCM2 Malcavernin , and CCM3 PDCD10) and four possible loci responsible for
the pathogenesis of these lesions. CCM1 functions through integrin signaling and regulation of
RAC1 activity and may be involved in the MAPK and JNK signaling cascades. We hypothesized
that CCM2 likely functioned through the same pathways and that CCM3 expression is regulated
by these stress-induced signaling cascades.

We showed that CCM2 likely functions through the MAPK pathway as the mouse homolog,
osmosensing scaffold protein for MEKK3 (OSM), has been shown to interact in the p38 mitogen
activated protein kinase (p38 MAPK) signaling pathway regulated by RAC1. We confirmed that
CCM1 and CCM2 signal as a complex since co-immunoprecipitation indicates joint expression.
We also characterized the role of CCM3 in the MAPK pathway by identifying interacting serine
threonine kinases (STK) and KIAA0826 based on yeast two-hybrid data. This was further
examined through immunohistochemical analysis showing CCM3 is expressed in a variety of
human organs especially arterial vascular endothelium in a similar pattern to CCM2. The yeast
two-hybrid data supports current theories that there is a link between CCM pathogenesis and the
ERK-MAPK cascade. These findings correlate with previous studies and further elucidate the
signaling pathways involved in CCM pathogenesis which may in turn be helpful in future
therapeutic advances.
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INTRODUCTION

Stroke is the third leading cause of death and a leading cause of disability in the
US. The majority of cerebral infarctions are ischemic in nature but hemorrhagic
infarctions account for 20% of cerebral vascular accidents. The primary risk
factors for hemorrhagic stroke include hypertension, coagulation disorders and
cerebral vascular malformations. These factors are implicated in 5-7% of
intracranial hemorrhages 1. Vascular malformations are described by their size
and location with the four most common categories being capillary
telangectasias , cavemous malformations, venous malformations, and
arteriovenous malformations (AVM) 2.

Clinical Aspects of Cerebral Cavernous Malformations

Cavernous malformations are the most commonly identified cerebral vascular
malformation accounting for 8-15% of central nervous system vascular
malformations 2 . An estimated 2 million Americans have CCMs and have a 50-

70% risk of hemorrhage, epilepsy or neurological deficit during their Iifetime4
Cerebral cavernous malformations (CCM) are found in 0.5% of the general
population as sporadic (15-33% of patients) or familial (73%) lesions3 . In general,
sporadic CCMs are single lesions while the autosomal dominant form presents
with multiple lesions. The sporadic CCM form tends to be asymptomatic, while
the familial form exhibits both phenotypic and genetic heterogenecitys.

2

eeMs are often an incidental finding on MRI appearing as a raspberry-like
angioma or popcom lesion 2 (Fig 1). eeMs are small hemorrhages isolated

Gunet .. aI. PNAS. 1995: 92(14):6820-6624.

GUnel ei aI. PNAS 2002: W(1 6 ):10677- 10082.

Fig 1. MAt images with classic popcorn-like appearance 01 cerebral

cavernous malfOfmations. Arrows point to lesions.

to the location of the lesion with hemoglobin degradation products such as
methemoglobin , hemosiderin and ferritin present 6 . These lesions are often
dynamic in nature and the mechanism of grow1h is thought to be due to repeated
microhemorrhages or recanalization after intraluminal thrombus? Functional MRI
imaging may become essential in the evaluation of eeM lesions 6, B

Fig 2. Histological images characterized by welt circumscribed clusters of dilated thin-walled vessels
that are surrounded by a giiotic rim . (A) Surgical specimen (hUp:lfwww.bram -aneurysm.comlcm.hlml) (8 )
Intraoperative image of CeM marked by arrow with corresponding histology (0) (Neurosurg Focus 2006
American Assoctn Neurological Surgeons) (C), (E) Histology of CeM (Mazza el al. Child's Nerv SyS\ ( 1991 )

7:139146)
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On histology, CCMs are 2-3mm to several centimeters in diameter and appear as
clusters of well circumscribed , abnormally dilated thin-walled vessels surrounded
by a gliotic ring (Fig 2). Clusters of sinusoidal vessels are often found outside
these capsules 9 . The walls of CCMs lack elastin and smooth muscle cells and
are lined by a single layer of endothelial cells 10 The pathology develops as the
vessel walls become distended because they lack elastin, thus slowing blood
flow through the vascular space 3 .

Cavernous malformations are located in the brain, spinal cord, skin , retinal
vasculature, liver, and kidney. Cerebral cavernous malformations (CCMs) are
dynamic and change in size over time ranging from 0.1 to 9cm and are usually
located in the cortex. CCMs are most commonly found in the frontal and temporal
lobes with 80-90% being supratentorial usually in the deep cerebral white matter,
corticomedullary junction or basal ganglia. The most common posterior fossa
sites include the pons and the cerebellar hemispheres 11.

Cerebral cavernomas bleed at a rate of 0.7-1.1 % per year. There has not been
significant data correlating CCM size with the risk of bleeding or neurological
deficits. In approximately 8-44% of patients, CCMs are associated with other
vascular malformations such as capillary telangiectasias 11 . The presence of more
than one type of malformation is associated with increased risk of hemorrhage .
CCM lesions prone to hemorrhage may have two hits , making them biallelic and
creating two nonfunctional copies of a CCM gene 12 , 13 .

4

The clinical symptoms of CCM include recurrent headache, intractable seizures
(40-50%), and hemorrhagic stroke (10-25%) which may lead to neurological
deficits (20% of patients) without surgical resection of a symptomatic lesion 14 ,
Current treatment is resection of the symptomatic lesion and careful monitoring
of small asymptomatic lesions 15 , Clinical studies have shown that patient age,
gender, symptoms, localization and size of the cavemous malformations are
important factors in determining timing of surgical resection 16,

17,

Preoperative

imaging is necessary to determine the vascularity of the surrounding tissue,
Cavemous malformations do not respond to conventional radiotherapy or
radiosurgery and necessitate microsurgical resection 18 ,

Cavemous malformations provide an excellent genetic model for the study of
familial stroke syndromes, There is significant evidence for autosomal dominant
inheritance among monozygotic twins, Studies show that 10-20% of Caucasian
CCM patients have a first degree relative with a cavemoma, A Dutch study
showed that 10% of monozygotic twins were likely to suffer a fatal stroke as
opposed to 5% of dizygotic twins 15 , Hispanic-Americans have a higher
prevalence of CCMs than the average population, suggesting a founder effect
19 ,

17

,

Affected individuals may share a common ancestor in Sorona County, Mexico

and there are other "Italian-American" and French fam ilies who exhibit the similar
linkages 20 , 21, The mechanism through which gene mutations produce CCMs is
not clear. However, suggested models include a two-hit mechanism in which one
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mutation occurs in somatic cells and one is inherited or two somatic mutations
may occur 1S

Familial cases are due to mutations in one of three loci: CCM1 on chromosome
7q21.2 , CCM2 on 7p15-p13, or CCM3 on 3q25.2-q27. These chromosomal
abnormalities are associated with the genes KRIT1 or Krev1 /Rap1 A interaction
Irapped 1 (CCM1) , MGC4607 or Malcavernin (CCM2) , and PDCD10 or
Programmed Cell Death 10 gene (CCM3) . Normal levels of KRIT1 , Malcav, and
PDCD10 expression are necessary for angiogenesis. The three characterized
CCM gene mutations are frameshift or nonsense mutations which result in
premature truncation of protein products . CCM1 mutations are responsible for
40% of familial cavernous angiomas. CCM2 mutations account for 20% of
cavernomas. The remaining 40% of CCM patients have lesions associated with
CCM3, a fourth CCM mutation, or a combination of the above mutations

22

.

Background and Expression of CCM1

The CCM1 gene KRIT1 was identified using yeast two-hybrid screening looking
for proteins interacting with the bait Krev1 / Rap1A mutations in Hispanic
families 23 . The majority of Hispanic-American cases and 40% of total familial
CCM cases are attributable to CCM1 mutations 24 However recent evidence
suggests that external factors in addition to the CCM1 germline mutation may be
involved in phenotypic manifestation of the CCM pathology25. The fact that KRIT1
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is expressed in many tissues throughout the body but CCMs are a pathology
found only in the central nervous system further confirms this theory26.
Approximately half of symptomatic CCM1 patients hemorrhage in comparison to
23
87% of patients with CCM2 or CCM3 familiallesions .

CCM1 encodes a 529aa protein with four ankryin domain which interact with
27
RAP1A's carboxyterminal region . RAP1A was isolated through its interaction
with DRAS3 which is a Drosophila melangogaster homologue 28 . Ras signaling is
thought to participate in angiogenesis as suggested by abnormal vascular
development in mouse models 29 . 3o and its interaction with B-Raf which , when
deficient, initiates endothelial apoptosis in mice 3o . RAP1A also participates in
morphogenesis and cell differentiation 31. Recent studies have confirmed that
RAP1 A signal transduction pathway is involved in vasculogenesis or
angiogenesis which also links CCM1 to this cellular function 32 .

KRIT1 contains an ankyrin and FERM domain which implies a link between
integrins and the actin cytoskeleton 3. The interaction between KRIT1 and RAP1A
supports a loss of function hypothesis for CCM development and a phenotypic 2hit model. KRIT1 splice variants expressed early in angiogenesis interact with
RasGTPases and microtubules. Integrin signaling plays an important role in CCM
pathophysiolgy suggesting that KRIT1 regulates bidirectional signaling between
the extracellular matrix and cellular cytoskeleton.

7
KRIT1 may also be involved in the communication between astrocytes and
endothelial cells. The CCM phenotype is characterized by leaky CNS vessels , a
fact which is supported by knowledge that GTPase KRIT1 is expressed in
endothelial cells and localizes to astrocytic foot processes, suggesting a defect in
blood brain barrier (BBB) formation 35 .

Many signaling pathways have been recognized as potentially important in CCM
pathogenesis. KRIT1 contains a NPXY domain which binds Integrin Cytoplasmic
Domain Associated Protein-1 a (ICAP-1 a) , which in tum is a binding partner of

~-

1 integrin 36 . Examination of the molecular function of at least one KRIT1 splice
variant indicates expression during early angiogenesis and identified interaction
with RasGTPases and microtubules . The Krev1 /Rap1 a gene - GTPase Ras
KRIT1 interacts with ICAP1 which binds

~-1

integrin and Rac1. The longer KRIT1

splice variant also interacts with Integrin Cytoplasmic Domain Associated
Protein-1a (ICAP-1a), which is a binding partner of

~-1

integrin. These

observations implicate integrin signaling in CCM pathophysiology and further
suggest that KRIT1 could mediate signaling between the extracellular matrix and
the cellular cytoske leton 24 , 3l This supports integrin signaling in CCM
pathophysiology, implying that KRIT1 mediates signaling between the
extracellular matrix and cellular cytoskeleton.

A KRIT1 -/- knock-out mouse model revealed that loss of the gene results in
dilation of large vessels 33 . This deletion led to death in many of the knock-out

8

animals however it has been shown that mice heterozygous for KRIT1 did not
develop the vascular lesions 26 . 33 . Knock-out mice died at embryonic day 8.5 from
closure of the dorsal aorta due to endothelial proliferation 34 . KRIT1 may function
in Notch4-mediated arterial development, regulation of RAC1 activity and integrin
signaling 3 .

CCM1 exhibits predominately nuclear expression in response to stress and is
found in the arterial endothelium of mammalian tissues 10. Within the cerebral
cortex, CCM1 is evident in the arterial endothelium as well as the astrocytic foot
processes 24 . One clinical study found a family with several patients documenting
a CCM1 vertebral lesion with cutaneous lesions present 22 . This is unusual as
CCMs are predominately a CNS lesion.

Background and Expression of CCM2

The CCM2 gene MGC4607 has been correlated with 20% of familial CCM
cases 38 . The murine homologue of CCM2, osmosensing scaffold protein (OSM) ,
was identified as an interacting partner of Mitogen-activated protein kinase 3
(MEKK3) which activates ERK, JNK, and p38 MAPK signaling depending on the
cell context and stimulus. There are two primary splice variants at 49 kDa and
84kDa 39 .

9
CCM2 shares CCM1's expression pattern in mammalian tissues. Previous data
has shown expression in brain, heart, lung , kidney, liver and spleen . More
specifically, CCM2 is expressed in the arterial endothelium of the vasculature of
these organs and is predominately cy1oplasmic 4o In the lungs, CCM2 is
expressed in the capillary lining of the alveolar walls, bronchioles, columnar
epithelium and epithelial cilia but not in the venous endothelium. Aortic
endothelium expresses CCM2 as well. The myocardial and pericardial layers of
the heart exhibit CCM2 expression in the arterial endothelium as well as the
coronary arteries. Within the liver, CCM2 expression is evident in the hepatic
artery and bile duct endothelium, as well as in hepatocy1es. CCM2 is expressed
in the endothelial lining of the blood-thymus barrier and splenic endothelium .
Renal interconnected glomerular capillaries express CCM2 as well. Within the
cerebral cortex, CCM2 is expressed in the cy10plasm of the pyramidal neurons
and glial cells especially in the astrocy1ic foot processes 40 .

The MGC4607 gene is responsible for CCM2 lesions. A yeast two-hybrid screen
of T-cell cDNA library using the CCM2 murine homologue, OSM , as bait
identified Mitogen-activated protein kinase 3 (MEKK3) as a binding partner.
MEKK3 activates the ERK, JNK, and p38 MAPK signaling pathways. The
activation of a specific pathway by MEKK3 is dependent of the cell line and
stimulus used . Following hyperosmotic shock, OSM induces p38 expression
through the MAPK signaling pathway as a scaffold protein.

10

CCM2 also interacts with ICAP-1 which interacts with the RhoGTPases and
~ 1integrin

which are important in cytoskeleton. CCM2 and ICAP1 bound to

CCM1 via PTB domains may influence the subcellular localization of CCM1
Further, recent evidence suggests that CCM2 and CCM1 interacts with MEKK3
in a complex 41 . This suggests that CCM1 and CCM2 may interact as a complex
regulating RAC1 which activates the MAPK cascade.

Background and Expression of CCM3

The CCM3 gene PDCD1 0 was discovered through examination of a large
deletion in a CCM family. The PDCD10 gene expression was found to be upregulated in TF-1 premyeloid cell line after growth factor deprivation and a
fibroblast cell line after induction of apoptosis 42 , 43. PDCD10 is highly conserved
in vertebrates and invertebrates 43 . PDCD10 is upregulated during apoptosis in a
human premyeloid cell line and may function in regulation of cell proliferation and
apoptosis 3 . Knockdown of the C. e/egans homolog of PDCD1 0 (2KB06) results
in increased embryonic lethality although the biological functions of PDCD1 0
have not been fully characterized . Knockdown C.e/egans survivors exhibit a
shorter and fatter phenotype.

In contrast to some studies which have shown that up to 50% of CCM1 lesions
may be asymptomatic, CCM3 lesions are highly symptomatic 26 . Patients with
CCM3 lesions present with symptoms at a younger age and exhibit a higher risk

II

of cerebral hemorrhage, especially during childhood

44

Several families have

been identified with this mutation and the cellular function of POC01 0 in relation
to angiogenesis and cerebral vessel remodeling is still being investigated 43 .

Background and Expression of CCM4

The remaining 40% of CCM mutations were formerly all associated with CCM3
mutations, however more recently a fourth locus was identified on chromosome
3q26.3-27.2 that appears to be unique from CCM3 on 3q25.2-q27 22 . 45. 46 . The
proximity of these two loci to one another may make it difficult to link this new
locus to a novel protein. The K2015 family has a strong link to the POC010
locus. A recent study has shown a distinct recombination event between
0353053 and GATAB1 H05 which excludes the POC01 0 gene indicating the
presence of a fourth mutation 46 .

MAPK Pathway and Serine Threonine Kinases

Although the mechanisms of cerebral angiogenesis are not understood , the
MAPK and JNK pathways have been implicated in cerebral angiogenesis. The
molecular mechanism behind CCM pathology has not been identified although
three transcripts and protein products have been characterized.

12

The MAPK signaling cascade has been shown to be activated by environmental
stressors such as osmotic changes which can result in various pathologies
depending upon the organ system involved . In the eye , corneal epithelium
exposed to hypertonic states results in decreased cell proliferation 4l Osmotic
stress has also been implicated in the activation of the TAK1-JNK pathway which
is mediated by NF-KB activation 4B The GGM proteins have been shown to
interact with the highly conserved Ras proteins that act as central regulators for
several pathways in response to stress 49 .

Mitogen activated protein kinase (MAPK) family members are responsible for the
maintenance of cells. MAPK regulates apoptosis in response to external stress
signals 5o • The MAPK cascades are critical in using extracellular stimuli for
intracellular signaling. There are three well known MAPK subfamilies, the
extracellular signal-related kinase (ERK), c-Jun N-terminal kinase (JNK) and the
p38 mitogen activated protein kinase (MAPK) signaling cascades. ERK signaling
acts against Rho-kinases to promote endothelial cell survival and sprouting
during angiogenesis 51 . RAS-RAF-MEK-ERK signaling is thought to be important
in tumor angiogenesis or cell proliferation in pathologies such as GGMs 52 . JNK
and p38 MAPK are the primary stress-induced cellular responses best
documented through osmotic cellular changes. These two pathways are also
responsible for apoptosis and the removal of dysfunctional cells. NF-KB is an
activator of cell survival signaling 53 . Proinflammatory cytokines such as TNF
activate both NF-KB and the JNK pathways through TAK1 which is a

13

transforming growth

factor- ~-activated

kinase thought to be regulated by osmotic

stress 54 , 5S

Tumor necrosis factor receptor-associated factors (TRAF) are multifunctional
signal adaptors which activate kinase cascades such as c-Jun N-terminal kinase,
p38 mitogen activated protein kinase and the transcription factor NF-KB56 There
are six identified TRAFs 5l The JNK pathway is initiated by mediators such as
TNF- ex and IL-1 interacting with TRAF-6, TRAFs act as protein scaffolds and link
the TRAF domain to the IL-1 receptor pathways in order to regulate apoptosis
and cytokine signaling 58 , Serine/threonine kinases are known to regulate the NFKB pathway after TNF-ex and IL-1 cytokine activation 57 , 59 . One study examined
astrocytes infected with Escherichia coli, which causes inflammation such as
meningitis or an abscess, Examination of proinflammatory mediators indicated
that TNF- ex and other participates in the NF-KB pathway may contribute to
inflammation in the brain 55 , Another study found that the NF-KB pathway in
epithelial and lymphocytic cells was suppressed with adenosine which is an
endogenous immunomodulator that has anti-inflammatory and
immunosuppressive properties 60

The six TRAF proteins each have a different role in cellular responses such as
the activation of apoptosis or promotion of cell survival. TRAF-1 is associated
with lipid rafts which participate in apoptosis in the traumatized brain and
neurogenerative diseases 6 1 , TRAF-2 activates the NF-KB pathway in order to

14
promote cell survival 53 , 62, 63. TRAF-2 has a splice variant with an extended RING
finger domain which inhibits this activation as well thus providing its own direct
feedback64 TRAF-3 also participates in apoptosis 65 , TRAF-4 expression has
been shown to be critical to the ontogenesis of the CN8 and PN8 during mouse
embryogenesis and is expressed intracellularly in the adult hippocampus and
olfactory bulb which are active in neoneurogenesis 66, 6l TRAF-6 mediates
signaling from the amino-terminal domain of CD40 signaling , TRAF-6 activates
NF-KB and function independently of the other TRAF family proteins 68 Thus
TRAF-6 directly induces angiogenesis by activating NF-KB and c-Jun N-terminal
kinase 69 It is interesting to note that lipopolysaccharide (LP8) initiates TRAF-6
mediated endothelial survival 70

There are 28 members of the 8te20 kinase group in humans with homologues in
drosophila and Caenorhabditis elegans7 1 . The 8te20 kinases respond to osmotic
stress to initiate signaling cascades 72 , The biological function of mammalian
8te20 kinases (putative yeast mitogen-activated protein kinases kinases kinase
kinase , or MAP4k) is largely unknown but they are known to be germinal center
kinases that are involved in mating path ways73, 8te20 kinases are critical to
regulation of the cell cycle, apoptosis, and stress responses, Recent data
suggests that 8te20 kinases also participate in cell volume sensing and CItransport regulation 74 . As upstream activators of the MAPK cascade the 8te20
family regulates apoptosis, morphogenesis and cytoskeletal rearrangements and
71
thus may be implicated in pathophysiology of many human diseases .
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Ste20 is a PAK and germinal center kinase (GCK) family member74 . Ste20 is also
a p21-activated kinase (PAK) family member which is a MAP4K for three yeast
MAPK cascades. Ste20 group kinases are upstream activators of MAPK which
serve to regulate transcription. The Ste20 N-terminus noncatalytic domain binds
to and inactivates its kinase domain. Once GTP Cdc42 binds to the CRIB domain
of the N-terminus the Ste20 kinase is activated 75 . Deletion of the N-terminal
domain is a dominant gain-of-function allele 76

C. e/egans is a good model for studying the stress activated signaling cascades
responsible for apoptosis and cell survival. The loss of GLA-3 in results in
increased apoptosis. GLA-3 has been shown to participate in the MAPK signaling
pathway by interacting with MPK-1 which is a meiotic regulator. Thus GLA-3 acts
as a negative regulator of the MAPK pathway. MPK-1 is the C. e/egans homolog
of the mammalian ERKl2 and serine/threonine kinases and is required for
germline development. Thus C. e/egans organisms lacking MPK-1 exhibit
sterility and increased germ cell apoptosis n

The yeast two-hybrid assay is an effective tool for recognizing protein-protein
interactions. The mating pathway in the Saccharomyces cerevisiae is one of the
best understood eukaryotic signal transduction pathways. The mating signal is
carried from the plasma membrane to the nucleus via G-protein coupled
receptors and the mitogen-activated protein kinase (MAPK) signaling cascade.

16
The MAPK pathway is regulated by scaffold proteins and the dephosphorylation
of kinases which control the pathway via negative feedback based on
concentrations. Once the G-protein is activated, it initiates the MAPK cascade by
conveying a signal to effectors in the transmembrane scaffold protein Ste5
(serine/threonine kinase) which activates Ste11 (MAPKKK), Ste7 (MAPKK) , and
phosphorylates Fus3 (MAPK). MAPK voyages to the nucleus and delivers the
signal to downstream effectors which arrest the cell cycle in the G1 phase to
allow for mating . Thus the yeast mating system is itself a model for the MAPK
cascade and mating yeast strains which hold different proteins allows the
researcher to determine whether the two proteins interact

78

The Cre/lox system allows for inducible gene targeting for the expression or
ablation of any gene to any tissue at a defined time in transgenic mice. This
allows one to build novel chromosomes and further explore mammalian
development 79 . While C.e/egans and yeast provide models for identification of
mutant genes and protein interactions, the mouse offers a valuable mammalian
genetic model Bo

Based on the recent observation that the mouse homolog of CCM2,
osmosensing scaffold protein for MEKK3 (OSM) , participates in the p38 mitogen
activated protein kinase (p38 MAPK) signaling pathway, it has been
hypothesized that human CCM molecules might signal through this pathway as
well. Both CCM1 and CCM2 have been shown to signal through the p38 MAPK
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as well as the c-Jun NH2-terminal kinase (JNK). Together with the confirmation
of MAPK involvement in CCM signaling in humans, Ras GTPase activating
proteins may also playa role in CCM pathogenesis by modulating the MAPK
signaling cascades through direct association with CCM2. We sought to prove
this interaction using a yeast two-hybrid assay. The RasGAP proteins identified
as binding partners of CCM2 are predominantly expressed in the CNS which
may explain why CCM pathology is restricted to the CNS although the proteins
are expressed throughout mammalian tissues.

CCM1 has been shown to regulate

~1

integrin-mediated cell adhesion through

ICAP1. CCM1 may regulate RAC1 activity through ICAP1 guanine dissociation
inhibitor activity and CCM2 acts as a scaffold for RAC1 /MEKK3/MKK3 which
activates p38 through phosphorylation of MAPK. This relationship suggests the
possibility that CCM1 and CCM2 may act together as a complex3 . There is
evidence that interaction between CCM1 /CCM2 is prevented by a CCM2
missense mutation . This supports theories that CCM lesion pathogenesis may be
linked to the interaction between CCM1 and CCM2

4 1.

The aim of this project was to elucidate the relationship between CCM1 and
CCM2 in the activation of the p38 MAPK signaling cascade and to further
characterize CCM3 by analyzing expression in extracerebral and cerebral tissues
in relation to CCM1 and CCM2. The molecular mechanisms underlying CCM
pathophysiology are largely unknown. We sought to demonstrate that CCM1
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and CCM2 function as a complex to activate the p38 MAPK and c-Jun NH2terminal kinase signaling pathways and that CCM3 may signal through the p38
MAPK cascade. We also sought to confirm the interaction between CCM3 and
serine threonine kinase binding partners identified through the yeast two-hybrid
assay in order to understand the role of CCM3 in the activation of molecular
pathways responsible for CCM pathology.
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MATERIALS AND METHODS
In Vitro Cultures
Human umbilical vein endothelial cells (HUEVC) were cultured in M199 media
supplemented with 20% FBS, 200mmol/mL L-Glutamine, 1% Penstrep
(Invitrogen) , and endothelial cell grow1h supplement.

Neuro2A (N2A) cells were cultured in MEM with Earle's BSS and supplemented
with 10% FBS , L-glutamine , sodium pyruvate and non-essential amino acids.
N2A cells were purchased from ATCC

COS? cells were grown in low glucose OM EM (GIBCO/BRL) with 10% FBS and
1% antibiotic-antimycotic. Cells were grown to confluence on 100x 15mm Petri
dishes and harvested for protein for Western blot analysis and coimmunoprecipitation.

Pre-designed and annealed siRNAs (CCM1 10#15655; CCM2 10#33399; CCM3
10# 19312; Negative Control 10#4611 ) were purchased from Ambio. siRNAs
were transfected into cells using Oligofectamine (Invitrogen) at a final
concentration of 100nM in OptiMEM (Invitrogen) per the manufacurer's
instructions. Following initial transfection, cells were cultured in normal serum
media for 4 hours and re-transfected with siRNA at 1OOnM concentration and
then cultured for an additional 24 hours prior to harvesting for subsequent
analysis.
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Co-immunoprecipitation
COS? cells were transfected at 90% confluence with 4ug of CCM1, CCM2 cDNA
in pDEST52 vectors following the lipofectamine 2000 protocol. COS? cells were
also co-transfected with 2ug of CCM1 and CCM2. Cells were incubated 36 hours
at 37"C and ceillysates were collected using 1X Igepal CA-630 Co-IP buffer.
Lysates were precleared with Protein A-Agarose beads (Pierce) and spun down
at 4000rpm for 4min at 4°C. The supematant was incubated on a nutator
overnight at 4°C. This product was combined with Protein A-Agarose beads at
4°C for 1 hour and centrifuged at 4000rpm. The supernatant was washed with 1X
Co-IP lysis buffer, boiled and fractionated on a SDS-PAGE and transferred. via
western blot.

CCM3 Antibody characterization
A CCM3 specific antibody was synthesized and affinity purified by Zymed
Laboratories Inc. (San Francisco, CAl. The specificity of CCM3 antibody was
tested by transfecting COS? cells with an expression vector encoding a CCM3GFP fusion protein. Full length CCM3 gene was cloned into pcDNA-DEST53
plamsid (Invitrogen, Carisbad, CAl and COS? cells were transfected with either
this construct as the positive control or Lipofectamine (Invitrogen, Carisbad, CAl
as the negative control.

The transfected cells were lysed and products fractionated with SDS/PAGE. The
protein samples were run on 10% Tris-HCL gels (BIO-RAD, Hercules, CAl for
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fractionation by electrophoresis followed by transfer to PVDF membrane. Blots
were blocked in 5% nonfat dried milk in PBS with 0.05% Tween 20. Blots were
then incubated with a 1: 1000 dilution of primary antibody ovemight at 4°C
followed by secondary incubation with horseradish perioxidase conjugated
affinity purified donkey anti-rabbit IgG (Jackson Immunoresearch Laboratories,
Inc, West Grove, PAl. Protein bands were visualized using electrochemical
luminescence reagents (Amersham Biosciences, Piscataway, NJ). For peptide
competition assays , the primary antibody was incubated with twofold molar
excess of the immunizing peptide prior to the primary incubation .

Analysis of CCM3 Expression in Mouse Tissue
In order to analyze CCM3 and CCM2 protein expression in various tissues ,
organs from a CD-1 mouse were homogenized and 15fl9 of the resulting protein
Iysates were analyzed by Westem blot. Protein concentrations were determined
using BSA standards and a Bradford Coomassie Protein Assay Kit from Pierce
(Rockford , II) . Primary antibodies for Westem blots were used at a 1:1000
dilution. Membranes were treated as stated above.

Tissue Collection
Sections of human organ tissue were obtained from the Department of Pathology
at Yale University School of Medicine (Human Investigations Committee Protocol
No , 7680). The tissues were fixed ovemight in 4% paraformaldehyde, embedded
in paraffin , and sectioned 0.5mm thick.
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Immunohistochemical Analysis
Sections were incubated for two hours in a 60°C oven to deparaffinize and
incubated in Xylene for 10 minutes followed by short incubations through an
alcohol gradient: 100%, 90% and 70%. In order to optimize CCM3 antigen
exposure, the slides were placed in 1Ommol/mL citric acid solution and
microwaved. A hydrophobic barrier was drawn around the tissue with ImmEdge
Pen (Vector Laboratories, Inc, Burlingame, CAl. Sections were then rinsed with
1xPBS, blocked in H2 0 2 for 20 minutes to minimize nonspecific staining, and
rinsed again in 1xPBS. A visualization system kit from Lab Vision Corporation
(Fremont, CAl was then utilized. The sections were incubated in Ultra V block
solution for 10 minutes and without rinsing, a drop of primary antibody was
added. The tissue was stained with the CCM3 antibody customized from Zymed
and characterized as mentioned above. As a negative control, some sections
were incubated in CCM1 or CCM2 antibody. After primary incubation the slides
were washed in PBS and then incubated for 30 minutes with biotinylated goat
anti-rabbit IgG antibody (Vector Laboratories Inc, Burlingame, CAl. The sections
were then put through a series of PBS washes and strepdavidin was applied for
10 minutes followed by further PBS washes. The chromogenic reaction was
induced with DAB substrate from Vector Laboratories, Inc. The reaction was
terminated with tap water and the slides were counterstained with hematoxylin.
The slides were then dehydrated, and mounted permanently and viewed under a
light microscope.
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Microarray Screening and Data Anaylsis
Total RNA from siRNA treated cells were extracted using QIA shredder followed
by RNeasy kit per manufacturer's instructions (Qiagen). Isolated mRNA was
processed for hybridization using 3DNA Array 900 kit (Genisphere) and applied
to Operon OHU21 K chips containing 21,000 70mer oligos. The results were read
using image analysis software GenePix S.O and imported into GeneSpring 6.2
,

(Silicon Genetics, Redwood City, CAl for gene expression data analysis. To
reduce the effect of outliers, the median values instead of the mean were used to
calculate both CyS and Cy3 channel intensities. The intensity values were
calculated by subtracting the local median background value from the median
foreground value for each spot. LOWESS normalization using 20% of data for
smoothing was performed to eliminate dye-related artifacts. The ratio of the
normalized intensity (CyS/Cy3) calculated by GeneSpring was used for
expression analysis. Genes with average intensity values less than 1000 for both
channels, or CyS/Cy3 ratio greater than 0.67 but less than 1.S (i.e. less than SO%
regulated), were excluded in the subsequent statistical analysis. A one-sample t
test using p-value cutoff O.OS with multiple test correction (Benjamini and
Hochberg false positive rate) adjustment to the p-value was applied to the
distribution of natural logs of the ratios for each gene to determine if the gene
was statistically differentially expressed.
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Immunofluorescent Staining
CCM1 full length mouse cDNA sequence was cloned into pEGFP_N3 expression
vector (Clontech) by inserting between Hindlll(5') and Xhol(3') sites. A full length
(1828bp) human CCM2 cDNA was cloned into the pOTB? vector from Open
Biosystems (MHS1011-60266) between the attB1 and attB2 site-specific
recombinases. A mammalian expression vector containing full-length CCM2
cDNA in frame with the GFP gene to its N-terminus was then created using the
Gateway Technology from Invitrogen with the use of an attR-containing
pcDEST53 vector. The GFP-tagged constructs were transfected into mouse
neuroblastoma (N2A) cells with Lipofectamine 2000 (Invitrogen) and cultured in
OPTI-MEME for 24 hours.

The cells were treated as detailed with 0.2M Sorbitol or 1Ong/ml TNFa (R&D
Systems Inc) for 15 minutes at 37"C and fixed in 4% PFA and blocked in 10%
normal goat serum followed by incubation with primary antibody (p-p38 or pJNK)
ovemight. Cells were then washed in 1X PBS and incubated with Alexa Fluor
555-conjugated rabbit secondary antibody and washed in 1X PBS before
mounting with DAPI-containing mounting medium (Vector). The fixed cells were
visualized using a ZEISS Axioplan microscope and the images captured using
the Axiovision software program.
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Yeast Two-hybrid Screening
The ProQuest yeast two-hybrid system was used for this assay. For the CCM3
screening, the interaction was confirmed by cloning full length CCM3 cDNA
sequence into a Clontech pGADT7 bait vector between the Xho and BamH1
sites. STK24, STK25 and KIAA0826 were cloned into a prey pGBKT7 vector
between Not1 and Sal1 sites. The pGBKT7 constructs were transformed into
AH109 yeast and the pGADT7 construct was transformed into Y187. These were
confirmed via western blot and checked for self activation on appropriate dropout
plates. The prey and bait were then mated overnight at 37°C. Constructs were
plated onto -Leu, -Trp, -Ade/LeufTrp, and -His/LeufTrp/Ade drop out plates and
incubated at 37°C for 3 to 4 days. Clones were selected on plates lacking
leucine, tryptophan, and histidine in the presence of 50mM 3AT. 2% 5-f1uoorotic
acid plates were used for negative selection. Mated cultures were confirmed via
PCR and sent for sequencing to KECK to confirm that successful mating.

In order to verify the protein interactions isolated by the yeast-two hybrid a
reversal of prey and bait vectors was done. By cloning 10ng of full-length human
CCM3 cDNA including 5' and 3' UTRs (Open Biosystem BC002506 MHS101159014) into a pDEST32 yeast expression pGADT7 bait vector (ProQuest yeast
two-hybrid system-Gateway Technology, Invitrogen) between the attR1 and
attR2 sites. This was set against a human fetal brain cDNA library (Invitrogen)
which was inserted into the pEXP-AD502 prey vector between the attB1 and
atttB2 sites. Clones were selected on plates lacking leucine, tryptophan, and
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histidine in the presence of 50mM 3AT. For negative selection, 2% 5-fluoorotic
acid plates were used. For the re-transformation assay, 10ng of CCM3 cDN A
was co-transformed with 10ng of test DNA in the MaV203 host yeast strain
(Invitrogen). Full-length CCM3 cDNA sequence was cloned into a Clontech
pGADT7 "prey" vector. STK24 and STK25 were cloned into a pGBKT7 "bait"
vector. The STK24 and STK25 plasm ids were transformed into the yeast strain
AH109 and the CCM3 prey was transformed in Y187 yeast strain. These two
yeast strains were then mated in a confirmation yeast two hybrid reaction and
plated on plates lacking leucine , tryptophan and histidine. For negative selection ,
combination plates were used lacking all three amino acids.

For the CCM2 yeast two-hybrid analysis the Proquest yeast two-hybrid system
with Gateway technology was purchased from Invitrogen. The bait was a full
length CCM2 cDNA sequence (IMAGE biosystems) including 5' and 3' UTRs was
cloned into pDEST32 between attR1 and attR2 sites. A human fetal brain cDNA
library (Invitrogen) was inserted into the pEXP-AD502 vector between the attB 1
and attB2 sites. These clones were selected on plates lacking -His/-Leu/-Trp/Ura in the presence of 50mM 3AT. A 0.2% 5Fluoorotic acid plate was used for
negative selection. CCM2-AD was used as a negative control for the selection
plate due to co-transformation of full length CCM2-DB with an empty vector
containing GAL4AD domain . For the retransformation assay, 1Ong of CCM2
cDNA was co-transformed with 10ng of test DNA in Ma V203 host yeast strain
(Invitrogen).
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PCR of CCM3 and STK24, STK25 and KIAA0826

Yeast colonies were picked and grown up in YPD broth overnight and presence
of the desired construct was tested by digesting the construct. The CCM3
constructs in the pGADT7 vector were digested with BamH1 and Xho1 while the
STK24, STK25 and KIAA constructs in the pGBKT7 vector were digested with
NOT1 and SAL 1 overnight at 60' . These products were run out on a 1% agarose
gel and to check for bands at 1.2bp for STK24 and STK25 and 1.3bp for
KIAA0826. These bands were excised from the gel and purified using gateway
technology gel extraction and the KIAA0826, STK24 and STK25 yeast colonies
were amplified using BDAdvantage enzyme in a 50ul reaction with matched
primers and using KIAA0826 primers with sal1-tag forward
(CCGGTCGACTACCAGAGCCTCTAGCTCCTGA) and not-tag reverse
(CGGGCGGCCGCGTTTCTTTCCTAAAGGCCTGA), STK24 primers with sal1tag forward (ccggtcgactgatggctcactccccggtgcagt) and not-tag reverse
(CGGGCGGCCGCCAAATGCCAAAGGAATTTCA) and STK25 primers with
sal1-tag forward (gcgccgtcgactagctcacctccggggattt) and not-tag reverse
(GGCGCGGCCGCTTCCGTCCCCTATCTGAACA). CCM3 primers used bamtag forward (ccgggatccGGATGACAATGGAAGAGATGAA) and xho-tag reverse
(CGGCTCGAGCTTTCAGGCCACAGTTTTGA). Product was run out on 2%
agarose gel with 100 base pair ladder. These products were sent to KECK for
sequencing.
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Gamze Tanriover and Arianne Boylan were both responsible for the
immunohistochemical data. Dana Shin performed the CCM2 yeast two-hybrid
and microarray assays. Arianne Boylan was responsible for all other data
presented here.
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RESULTS
Recent studies have shown that CCM1 and CCM2 activate p38 MAPK and JNK
signaling pathways due to cellular and environmental stressors. We sought to
confirm that CCM1 and CCM2 act as a complex to initiate p38 MAPK signaling
through a co-immunoprecipitation. In order to address the role of CCM3 in the
MAPK signaling and JNK cascades we used the yeast-two hybrid system to
isolate proteins interacting with CCM3.
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Fig 3. Coimmunoprecipitation with CCM1 and CCM2 transfecled in COS? cells indicates that the
proteins are endogenously expressed In this cell line and express as a construct. GFP and FLAG
antibodies were used as conlrols as GFP is endogenously expressed. CCM1 produces the
expected band at 62kOa and CCM2 at 49KOa. The GFP bands were expected to be 75kDa. Blot
A represents CCM1 primary antibody with an antirabbit secondary. Blot B represents CCM2
primary antibody wilh antirabbit secondary. Blot C represents antiGFP primary anlibody wilh
anlimouse secondary.
.

CCM1 and CCM2 act as a complex in initiating p38MAPK cascade
The interaction between CCM1 and CCM2 was analyzed through a coimmunoprecipitation between the two proteins. COS? cells were transfected with
CCM1, CCM2 or co-transfected with both and exposed to either a CCM1
antibody, CCM2 antibody, or to no antibody. CCM constructs tagged with gfp and
FLAG were used as controls in order to determine if the proteins were

30
endogenously expressed in this cell line (Fig 3). The COS? cells incubated with
CCM1 primary and anti-rabbit secondary antibodies produced the expected
results. Under these conditions, COS? cells transfected with CCM 1 and pulled
down with CCM2 antibody produced a band at 49kDa. Cells which were
transfected with CCM1, CCM2, the CCM1/CCM2 co-transfection, or nontransfected cells were pulled down with gfp antibody did not produce a band.
Cells transfected with CCM2 and pulled down with CCM1 antibody produced the
expected band at 62kDa.

Non-transfected cells pulled down with CCM1 produced a band at 62kDa and
nonctransfected cells pulled down with CCM2 produced a band at 49kDa. Similar
results were found for Iysates which were incubated in a CCM2 primary and antirabbit secondary antibody. Lysates were incubated in an anti-gfp primary and
anti-mouse secondary as a control. Only those cells which were pulled down with
gfp produced a band at the expected band width of ?5kDa (Fig 3). The Iysates
which were incubated with the anti-gfp and anti-mouse antibodies produce a
band corresponding to gfp and not CCMl or CCM2 showing that the coimmunoprecipitation accurately reflects interaction between the CCM protein and
antibody.
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CCM1 and CCM2 are involved in p38MAPK and JNK signaling
Microarray analysis of HUVEC cells after CCM1 and CCM2 knockdown indicated
that CCM1 and CCM2 but not CCM3 are involved in the p38 MAPK and JNK
signaling cascades. CCM1 and CCM2 silencing affected expression of several
genes which have been associated with these stress-responsive signaling
pathways. However, CCM3 knockdown did not affect the genes. This implies that
CCM3 does not activate these signaling cascades (Table 1) .

..

-...;.

=,

=u

=,

-

.........

"~.

..

IKlIOUlJ

W

"~

"'YC~I"""X

)o;~LOOU~

':.11

IIml

IIQI_ l7U> ,... ",, 1

'"

~1Ef'lC

~'AllS k» In~pO'" 'W"""

..1.11

MAPKAPI

SAPKi ....... i,Jp'OIti. ,

.,~

ITSD I

C). ,~.

S~UJO-l 6n

,."

MAP1K6

,11.", •••

XMOOlHI

_2.-10

""Kl

P111('J.;' ~I..."i"'''·dki .... l

J:<K,pJ.

·1.17

MI)oiK

~1i~.');U(...Ia«!I.i.,..

ISK.pll

.~

..""""'"

LOIt'lS

.,~

;':M_Ol~ 1l7

S ~LOS~

S~L¢1J716

S>I 0011,.

'"

·1.J7

01 (I'RA.DI'

."
/"",,1. ....

,1"'I"i"" C

(10)'<,<)" . . ho"",~ r...1<~

p>nI.,•.,w ».I<"""",..i. I I

~'"'"""k

.n
IX!;;

><,,,WdI,,,,,,i. Li.,.. Li..., IJ .... 6 (ASKlI

:II...,.o«o"...

ZC1

__

...,oJ ,...,;.a;_1

I XK

JXK,pJ'

fJlKIJl.r»

Table I. Genes in the MA PK sir-oilling pnth waJ$ aIT«ttd by CCM I and ca.U silencing.

Table above ibus\ratas the effects of CCM1 and CCM2 on p38 MAPK as well as JNK signalng pathways (Shin, D.
unpublished data).

CCM2 interacts with RasGAP proteins
GTPase Ras and other small proteins in this family are upstream signaling
molecules which regulate the MAPK signaling cascade B1 . CCM1 was initially
cloned as a binding partner of a small GTPase Ras-related protein (Rap1A) in a
yeast two-hybrid assayB2. Thus CCM1 and CCM2 might regulate MAPK signaling
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via Ras molecules. A yeast two-hybrid assay using CCM2 as bait against a
human fetal brain library, isolated three Ras GTPase activating proteins
(RasGap) (Fig 5a). Of 37 independent clones, 11 were Synaptic GAP (SynGAP) ,
four were Ras activating protein like-2 (RASAL2) and two were ASK1 interacting
protein 1 (AIP1 or DAB21 P) . The CCM2 yeast two-hybrid screen indicated that
CCM2 interacts with KIF5A (Fig 5) .

a
b

Fig 5. Identification of RasGAP protens as CCM2 binding partners. (a) Yeast two-hybrid screening
identified SYNGAP; AASAL2 as potential interactors with GCM2. Control E confers a strong
interaction phenotype,CCM2-AD is a negative control for the selection plate due to cotransformation of full length CCM2-0B with an empty vector containing GAL4AD domain. (b)
Assessment of their interaction by (e-transformation with clones obtained from primary
screening above. Growth of AIP1 as well as RASAL2-NPXY mutant is abrogated. SYNGAP
and RASAL2 show strong interaction phenotype on the same selection plate used as above.
0.2% 5FOA is a negative selection plate and shows a complementary growth pattern (Shin,
D. unpublished data).

The RASAL2 proteins contain a NPXY motif which binds the phosphotyrosine
binding (PTB) domain of several proteins 83 . CCM2 contains a PTB domain so we
wanted to determine whether this interaction specificity depended upon NPXY-

PTB binding . The interaction between CCM2 and RASAL2 disappeared when the
amino acid residue asparagines (N783) on the NPXY domain of RASAL2 was
mutagenized to histidine (Fig 5b) .
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Nuclear CCM1 and CCM2 translocate to cytoplasm in response to stress
CCMl and CCM2 have potential nuclear localization signal sequences. Based
upon PSORTII software analysis, we found that CeMl has two putative nuclear

No stimulus

TNFa(10ng/ml)

Figure 6. Nuclear CCM1 and CCM2 translocate to the cytoplasm following TNFo: treatment in N2A cells. As predicted
by the PSORTII program, CeM1 protein overexpressed in N2A (a) shows a predominant nuclear localization , while
CCM2 is overexpressed equally in both cytoplasm and the nucleus (b) . When the cells were treated with TNFct for 15
minutes, nuclear CeM1 as well as CCM2 proteins no longer remain nuclear, but translocate to the cytoplasm (c,d).
While arrows in c and d indicate the unoccupied nuclei after TNfa treatment. (Shin, D. unpublished data).

localization signals: KKKRKK (46-51) and KKHK (569-572). According to this
analysis the CCMl protein has a 69% chance of being found in the nucleus.
CCM2 has one nuclear localization signal, RHRR (387-390) with a 52% chance
of finding CCM2 in the nucleus.

To determine the subcellular localization of CCMl and CCM2 , mouse N2A cells
were transfected with GFP-tagged constructs containing each protein after TNFa
or sorbitol stimulation . CCMl was expressed mostly in the nucleus with weak
cytoplasmic expression after over expression and in the absence of stimuli.
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CCM2 was expressed equally in the cytoplasm and nucleus (Fig 6 a,b). The
subcellular localization of CCM1 and CCM2 changed to mostly cytoplasmic after
sorbitol or TNFa treatment for 15 minutes (Fig 6 c,d). CCM3 was localized to
both the nucleus and cytoplasm both before and after treatment (data not
shown).
2nn-4-----,

50

A

B

Fig 7. CCM3 [1 :500] antibody was used 10 stain Western blots 01 protein lysate extracted from
homogeni~ed mouse tissue. Staining detected a protein of the fI)(Jl9CtOO band size (43kDa) for CCM3 In brain (AI
blJl not In the Mgative control aortic tlssue(B).

Characterization of CCM3 antibody
Antibody specificity was determined for CCM3 by comparison of protein Iysates
from homogenized mouse aortic and brain tissue and stained with CCM3
antibody. Western blot stained a protein of expected band size of 43kDa (Fig 7).
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Fig 8. CCM3 was expressed across all tissues except aorta using CCM3 antibody staining on
Western blot of protein lysate from homogenized mouse tissue. The expected band size of 43kDa appeared
Across all tissues except for the aorta. A. Heart B. Lung C,. Pancreas D. Liver E. Aorta F. Brain G. Muscle
H. Spleen I. Kidney. Multiple bands were seen in brain, pancreatic and lung tissue.
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CCM3 expression parallels CCM1 and CCM2 expression in mouse tissue

In order to evaluate the pattern of CCM3 expression in different tissues Iysates of
various mouse organs were analyzed by Western blot. Sections of human tissue
from those organs which expressed CCM3 endogenously were stained with
CCM3 antibody to analyze expression in human organs . Protein extracted from
homogenized mouse tissue showed that CCM3 is expressed in lung , pancreas,
brain , muscle, kidney, liver and heart but not in the aorta (Fig 8).
Immunohistochemical staining of human tissue showed a similar pattern of
expression with venous but not aortic CCM3 expression in the aorta (Fig 8). This
correlates with the pattern of expression of CCM2 in tissues (Fig 4).

4.4
2.4

1.35
Fig 4. Western blot analysis of MGC4607 expression in 12 human ti ssues.
Bands are expected size of 2.4kb for CCM2. (Seker et al. Stroke. 2006;37:5 18.)

CCM2 is expressed in brain , heart, spleen , skeletal muscle, thymus, kidney, liver,
small intestines, placenta, lung , colon and peripheral blood leukocytes (Fig 4) .
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CCM3 parallels CCM2 expression in Arterial Endothelial Cells
The distribution pattern of CCM3 expression was determined by
immunohistochemical staining of paraffin-embedded human tissue. CCM3 was

Fig 9. Staining with CCM3-specific polyclonal antibody illustrates specific expression
panern in cerebrovascular structures. CCM3 is expressed in arterial endothelial cells
in a similar pattern to CCM2 in a. medulla b. cerebellum c.lhalamus d.cortex.

expressed in the perinuclear regions above the arterial endothelium in the
medulla, cortex, cerebellum and thalamus (Fig 9).
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Fig 10. CCM310calizes to various epithelia in the eXl racerebral organs. a. CCM3 is expressed in the splenic central arteries
and some venous endothelium of the red pulp on the left. CCM3 is expressed in the arlerial endothelium of the wh ite pulp of
the spleen on the right. b. CCM3 is strongly expressed in the arterial endothelium lung but low expression 01 cytoplasmic or
perinuclear staining c.There is low venous CCM3 expression in the aorta. d. CCM3ls expressed in the ductus and hepatocyte
cytoplasm of the liver

Extracerebral Tissue Expression
Spleen:

The CCM3 antibody is expressed in the central arterial endothelium but not in the
venous endothelium in the white pulp but this pattem was not replicated in the
red pulp of the spleen where CCM3 was expressed in some veins. On higher
magnification CCM3 was shown to have nuclear expression in the spleen (Fig
10a) .

.Aorta:

CCM3 was shown to be expressed in the endothelium or perinuclear region of
the aorta (Fig 1Ob).

Lung:

Lung tissue showed intense arterial endothelial CCM3 staining but venous
endothelium had very low levels of expression (Fig 10c).
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Liver:
CCM3 was expressed in the ductus and hepatocyte cytoplasm of the liver but
there was no venous endothelial staining (Fig 10d).

Nuclear Renal Expression of CCM3
Immunofluorescence of COS? renal cell line indicated nuclear CCM3 expression
in the kidney. CCM3-HA tagged constructs were transfected into COS? cells.
Cells transfected with CCM3-HA were incubated with Cy3, Dapi and gfp. A
CCM1-GFP tagged construct was used as a positive control and nontransfected
COS? cells were used as a negative control. The Dapi staining indicates that the
Immunofluorescent staining was successful in that the majority of cells stained
with CY3 also stained with the nuclear stain Dapi. Overlap of the Cy3 and Dapi
shows significant nuclear expression of CCM3. CCM1 was previously known to
have nuclear expression (data not shown).

CCM3 interacts with SerinelThreonine Kinases
The Y2H screen using CCM3/PDCD1 0 identified two members of the subfamily
of STE20-like kinases: STK24 or Mst3, which was shown to phosphorylate
p42MAPK, and STK25 or SOK-1, which is known to be induced by oxidative
stress. CCM3 also interacted with KIAA0826 which is a homolog of the sensory
axon guidance family member (sax-2) in C.elegans (Fig 11). These interactions
were further confirmed by a second yeast two-hybrid analysis using only CCM3
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Fig 11. Identification of STK24, STK25, KlAA0826 as CCM3 binding partners. STK24,STK25, KlAA0826 in pGBKT7
Clonlec/l bait vector which is -trp and CCM3 in pGADT7 prey vector which is --leu. The individual dones do not grow on
the full drop oul plate bullhe mated constructs grow which indicates thai the complex activates the reporter gene. Controls
are AH109, bait yeast strain, and YP187, prey yeast strain.

against STK24, STK25 and KIAA0826 with identical yeast two hybrid technology
by Invitrogen. The transformation was confirmed via westem blot and verified on
appropriate dropout plates for self-activation. The prey and bait were then mated
overnight at 300°C. Constructs were plated onto -Leu , -Trp, -Ade/Leurrrp, and His/Leurrrp/Ade (-HLTA) drop-out plates and incubated at 300°C for three to four
days. Mated cultures were confirmed via PCR using gene specific primers and
sent for sequencing to KECK to confirm that successful mating.

Additional yeast-two hybrid done to verify interactions between STK24, STK25,
and Kiaa0826. The - Trp plates yielded STK24 , STK25 , KIAA0826 colonies
which corresponds to the pGBKT7 constructs where the vector is - Trp. This
indicates activation of the reporter gene and confirms interaction between CCM3
and these proteins. The CCM3 construct in the pGADT7 vector is -Leu and so
did not yield colonies. The co-transformed plates with STK24 and CCM3, STK25

40
and CCM3 as well as KIAA0826 and CCM3 all yielded colonies indicating that
the nonCCM3 colonies grew. The -Leu plates yielded CCM3 growth for the
individual and co-transformed plates. The most stringent drop out plates -HLT A
showed no growth for the individual constructs but yielded colonies for the
cotransformed plates indicating the complex activates the reporter gene. The
bait yeast strain AH109 served as a control to indicate there was no
contamination of the single construct plates.

Matched

Reversed

Fig 12. PCR amplification of bacte rial STK25 in pGBKT7 and STK24 in pGBKT7 using matched and
reverse primers. Amplification with the appropriate STK24 or STK25 pri mer yielded the expected band
Of 1.3bp. The same colonies did not amplify usi ng the pri mer set for the othe r STK protein. indicating that
STK24 and STK25 are on different loci although they appear the same size and share significant overlap.

Stk24 and Stk25 both produce a band at 1.3bp and KIAA0816 produces a band
at 1.4bp. STK24 (13q31.2-q32.3) and STK25 (2q37.3) have a 73.7% overlap in
408 amino acid residues. Since the serine threonine kinases produce bands of
the same size and share significant homology we amplified colonies using
matched and reverse primers to confirm that these two proteins were on
separate loci. The colonies produced the appropriate size band when amplified
with matched primers but did not when amplified with the opposite primer set (Fig
12).
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CCM Signaling Links Neural and Endothelial Elements
Based on above data we constructed a hypothetical pathway in which CCM1 and
CCM2 link the extracellular matrix to the cellular cytoskeleton and nucleus
through integrin/Ras-MAPK signaling 3 . Induction of apoptosis through these
signaling cascades leads to CCM3 expression and cellular proliferation which are
exhibited in the CCM pathology (Fig 13).
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DISCUSSION
Cerebral cavemous malformations are caused by mutations in three known
genes KRIT1, Malcaverinin (MGC4607), PDCD10, and possibly a fourth gene
whose locus is close to PDCD10. Although mutations in the three distinct genes
have been associated with CCMs they remain identical clinically and
pathologically.

The role of p38 MAPK signaling in CCM pathophysiology correlates with
evidence that p38 MAPK signaling is induced by integrin activation and may
regulate other cellular processes such as actin remodeling and apoptosis 84 . 88 .
Data showing that p38a null mice die early in gestation with significant placenta
vascularization defects implicates the MAPK pathway in the regulation of
angiogenesis 89 .

Our data indicates that CCM1 and CCM2 are necessary for the activation of
stress-responsive mitogen activated signaling pathways p38 MAPK and JNK
pathways through sorbitol and yeast two-hybrid assays. Further these two
molecules appear to act as a complex to initiate the signaling cascade. Although
CCM3 does not participate directly in these pathways yeast two hybrid data
confirms direct interaction between CCM3 and STKswhich are implicated in
MAPK signaling. This is also confirmed through si"RNA mediated gene silencing
and overexpression studies. CCM1, CCM2 and CCM3 appear to be expressed in
similar tissue distribution across the body although the CCM pathology is CNS
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specific. In addition, the intracellular CCM expression is identical between CCM1
and CCM2 and CCM3 is expressed in both the nucleus and cytoplasm, further
supporting theories that CCM1 and CCM2 work as a complex that interacts with
CCM3 to yield CCM pathology.

Based on previous data we hypothesized that CCM1 and CCM2 but not CCM3
were implicated in the same molecular genetic pathway responsible for
communication between neural and glial elements in the CNS 38 • Inflammatory
states impact astrocytes as well as endothelial cells as studies have shown
increased COgS-driven apoptosis in response to inflammation factors such as
TNF-a, IL-1 ~ and INF-/o. Data presented here supports the theory that CCM1
and CCM2 work as a complex to activate the stress-responsive p38 MAPK, JNK
pathways and that CCM3 works independently in conjunction with the other
proteins. The CCM1 and CCM2 proteins act as components of the MAPK
cascade which activate CCM3 through apoptosis41 • Signaling pathways do not
progress in a linear manner but act as multiple signaling pathways regulating one
another to produce biological effects 91 •93 •

We showed that CCM1 and CCM2 are endogenously coexpressed in COS? cells
providing further evidence that these two proteins are involved in the same
biochemical pathway (Fig 3). This is an important step towards elucidating the
molecular signaling pathways responsible for CCM pathogenesis. Non-
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transfected cells pulled down with CCM1 or CCM2 but not the gfp antibody
indicates that CCM1 and CCM2 are endogenously expressed.

The theory that CCM1 and CCM2 act as a complex to initiate the p38MAPK
cascade,41 is supported by the fact that the CCM1/CCM2 co-transfected cell
Iysates pulled down with either the CCM1 and CCM2 antibody produces the
corresponding band width. Previous data has shown this activation to be in
response to osmotic stress. Our data confirms that CCM1 and CCM2 function via
the p38 MAPK and c-Jun NH2-terminal kinase signaling pathways and are
expressed as a complex in COS? cells. This supports previous data of a model
where CCM signaling links the extracellular matrix to the cellular cytoskeleton
and nucleus through integrin/Ras-MAPK signaling 94 .

Evidence of siRNA mediated gene silencing and overexpression studies support
this hypothesis (Table 1). Signal transduction of the integrin activated p38 MAPK
signaling pathway may mediate cellular processes such as actin remodeling and
cell apoptosis as well as vessel formation. The association between
angiogenesis and MAPK cascade is suggested by the observation that p38a null
mice are embryonic lethal and exhibit severe placental vascularization defects 89.

Although the molecular function of CCM2is still being established, CCM2's
mouse homolog, Osmosensing Scaffold for MEKK3 (OSM), has offered insight
into CCM2 function and interaction with CCM1 . OSM has a phosphotyrosine
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binding domain and is implicated in mechanosensing and osmosensing 83 . OSM
regulates p38 MAPK signaling through direct interactions with MEKK3, Rac and
actin 83 . The KRIT1 binding partner, ICAP10: inhibits Rac signaling, thus the Rac
molecule may be a critical point of interaction between CCM1 and CCM2 37, 95. 96.
Further, yeast two-hybrid data indicates that RasGAP proteins interact directly
with CCM2 which supports the theory that this molecule is involved in the MAPK
pathway and interacts directly with CCM1 to initiate involvement.

The RasGAP proteins identified as CCM2 binding partners through yeast twohybrid assays are either predominately or exclusively expressed in the central
nervous system (CNS)55. RasGAP proteins exhibit a spatial expression profile
which may explain why CCM pathology is limited to the CNS although CCM
expression is found throughout mammalian tissues (Fig 4; 8). One of the CCM2
binding partners RASAL2 is a close family member to RASAL 1 which is mutated
in hereditary capillary malformation-arterious malformation (CM-AVM). RASAL 1
encodes p120 RasGAP which binds Rap1A which may be a binding partner of
CCM1.

Further studies have not supported this interaction possibly because there are
two biologically active splice isoforms of CCM1 the other of which binds
ICAP10:97 . Clinically this is intriguing since CCMs ~ccasionally produce
cutaneous lesions similar to those of CM-AVMs98. This evidence corroborates
theories that CCM1 and CCM2are involved in the Ras-mediated MAPK signaling
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pathway. Additional yeast two-hybrid data suggests that CCM3 may signal
through the same pathways through interactions with serine threonine kinases
which are upstream in the MAPK pathway.

Yeast two-hybrid analysis of CCM2 also indicates that KIF5A interacts with
CCM2. The isolation of this protein as directly interacting with CCM2 has
interesting clinical implications and further supports theories that CCM1 and
CCM2 work in concert. CCM1/KRIT1 knock-out mice have been shown to die
early from closure of the dorsal aorta34 • This supports histological data which
shows CCM1 expression is restricted to arterial and microvascular endothelium
with neurons and astrocytes 99 • Another CNS specific condition, avintegrin
mutants die from intracerebral hemorrhage early in gestation 100. Histological
examination of these brains shows lesions which are phenotypically similar to
CCMs. Conditional knock-out avintegrin mutants that survive exhibit hindlimb
weakness which is similar to spastic paraplegia (SPG) which is a heterogeneous
disease in humans 101.102. An autosomal dominant form of the disease, SPG1 0,
is caused by mutations in kinesin 5A (KIF5A) gene which has been shown to
interact with CCM2
av~8integrin

101.

This suggests an interaction between CCM signaling and

which supports the theory that CCM signaling links neural elements

with endothelial cells and is important in cerebrovascular development lOO.

CCM1 and CCM2 have been shown to be necessary for activation of the stressresponsive mitogen activated signaling pathways, p38 MAPK and JNK in
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response to hyperosmotic shock (sorbitol) or TNFo: treatment. CCM1 has been
shown to be a positive regulator of the p38 MAPK and JNK signaling pathways
and CCM2 interacts with RasGAP proteins to initiate the MAPK cascade.

Based upon these results we conclude that CCM signaling evokes a novel
pathway allowing communication between neural and endothelial cells of the
neurovasculature4o • When this pathway is disrupted by a mutation in a CCM
protein , the normal CNS angiogenesis is altered and the changed communication
between neural and endothelial cells results in the CCM pathology. CCM1 ,
CCM2 and CCM3 show similar patterns of expression in structures critical to the
blood brain barrier.

We showed that CCM3 is expressed across all tissues studied including the
brain , heart and kidney (Fig 8-10) . Although protein lysate from homogenized
mouse tissue did not appear to express CCM3 on repeated antibody staining on
Western blot, the presence of CCM3 venous expression on
immunohistochemical staining of human aortic tissue suggests its presence in
the aorta (Fig 8). This correlates with previous data on CCM1 and CCM2
expression (Fig 4) as well as current theories on CCM pathology and arterial
morphogenesis 103 . The similar pattern of expression between CCM2 and CCM3
across various extracerebral tissues supports theories that these two proteins
may work through the same mechanism or signaling pathway in yielding the
CCM pathology.
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Unlike CCM2 protein expression, CCM3 appeared to be predominately
expressed in the cytoplasm in the medulla. CCM3 was expressed in the purkinje
cells of the cerebellum as well as glial cells in the molecular layer of the
cerebellum (Fig 9). These glial cells form part of the membrane encapsulating the
vessels which establishes the blood-brain barrier35 . Thus mutations in CCM
proteins in these cells may be responsible for the phenotypic leaky blood-brain
barrier associated with CCM pathology.

CCM2 is expressed by endothelial cells, specifically arterial and microvascular
endothelium in all tissues. In the brain CCM2 is also expressed in pyramidal cells
and astrocytes. CCM2 expression has been seen in astrocytes with foot
processes which terminate on c.erebral blood vessels. The glial membrane which
encapsulates the vessel and creates the blood brain barrier is established by
these foot processes35 . CCM lesions lack astrocytic foot processes and tight
adherence junctions between endothelial cells creating the appearance of an
immature vessel 104 . These lesions may have a proliferating, non-adherent
endothelium rich in fibronection and poor in laminin 105.

Previous data from this lab has shown high levels of CCM1 and CCM2
expression in arterial endothelium as well as microstructures important to the
integrity of the blood brain barrier. CCM lesions are CNS specific and CCM1
expression has been shown to be isolated to arterial and microvascular
endothelium of neurons and astrocytes including foot processes. This is
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supported by the clinical phenotype of KRIT1 knock-out mice which die early due
to closure of the dorsal aorta33, 34, To further support this hypothesis we found
CCM3 shares a similar pattern of expression in mouse and human tissue which
suggests that it is also implicated in normal angiogenesis and arterial
morphogenesis, Data has shown this CCM protein to be important in
cerberovascular development and remodeling 43 , CCM3 may also help regulate
apoptosis in smooth muscle cells which is mediated by

~1-integrin

signaling

which interacts with CCM1 and CCM2 as we1l 88 , The interaction between KRIT1
and ICAP1implicate CCM1 inthe

~1-integrin

signaling pathway,

CCM3 is important in cerebrovascular development and remodeling 43 , CCM3 is
caused by mutations in PDCD1 0 which is a gene involved in the initiation of
programmed cell death which is critical to arterial morphogenesis, Some
evidence shows that apoptosis in smooth muscle cells is mediated by ~ 1-integrin
signaling which interacts with CCM1 and CCM2 88 , Previous yeast two-hybrid
analysis of KRIT1/1CAP1 indicate ~1-integrin signaling involvement in CCM
pathophysiol ogy36, 37, Our data confirms that CCM1 and CCM2 are positive
regulators of p38 MAPK and JNK signaling pathways and that CCM3 expression
is related to these pathways,

In addition, CCM3 yeast two-hybrid data identified serine threonine kinases
which are part of the STE20 family which is upstream of the MAPK cascade. This
indicates that CCM3 may signal through the p38 MAPK cascade. Since CCM1
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and GGM2 are implicated in the p38 MAPK and JNK signaling pathways, their
activation of apoptosis may trigger GGM3. Another binding partner of GGM3,
KIAA0826 is an osmold scaffolding protein which provides further evidence that
the GGM proteins act in the communication between arterial and neuronal
elements (Fig 11).

Ste20-like kinases are a germinal center kinase that activate apoptosis through
the p38 MAPK signaling cascade. Interestingly, Ste20 expression is increased in
renal development and during the recover from acute ischemic renal failure.
Overepxression of Ste20 has been documented during anoxia/recovery-induced
apoptosis and is activated by homodimerization, signaling through ASK1 and p38
to induce apoptosis

106.

Further yeast two-hybrid assays are underway to find binding partners of STK24,
STK25 and KIAA0826 in order to dissect the molecular signaling pathway
responsible for GGM3 action.

These findings offer greater insight into the understanding of GGM pathology. We
suggest a model where GGM signaling links the extracellular matrix to the cellular
cytoskeleton and nucleus through integrin/Ras-MAPK signaling (Fig 13).
Identification of the signaling pathway(s) in which the GGM genes participate will
not only provide insight into the molecular mechanisms underlying cerebral
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angiogenesis and
approaches.

eeM pathology, but may also lead to new therapeutic

REFERENCES
1.
Sure U, Freman S,Bozinov 0, Benes L, Siegel AM, Bertalanffy H. Biological
activity of adult cavernous malformations: a study of 56 patients. Journal of neurosurgery
2005;102(2):342-7.
2.
Brown RD, Jr., Flemming KD, Meyer FB, Cloft HJ, Pollock BE, Link ML.
Natural history, evaluation, and management of intracranial vascular malformations.
Mayo Clinic proceedings 2005;80(2):269-81.
3.
Plummer NW, Zawistowski JS, Marchuk DA. Genetics of cerebral cavernous
malformations. Current neurology and neuroscience reports 2005;5(5):391-6.
4.
Awad IA. Unfolding knowledge on cerebral cavernous malformations. Surgical
neurology 2005;63(4):317-8.
5.
Koht J, Braathen GJ, Neubert D, Russell MB. [Cerebral cavernous
malformations]. Tidsskrift for den Norske laegeforening 2005;125(15):2008-10.
6.
Raychaudhuri R, Batjer HH, Awad IA. Intracranial cavernous angioma: a
practical review of clinical and biological aspects. Surgical neurology 2005;63(4):319-28 ;
discussion 28.
7.
Scott RM, Barnes P, Kupsky W, Adelman LS. Cavernous angiomas of the central
nervous system in children. Journal of neurosurgery 1992;76(1):38-46.
8.
Lehnhardt FG, von Smekal U, Ruckriem B, et al. Value of gradient-echo
magnetic resonance imaging in the diagnosis of familial cerebral cavernous
malformation. Archives of neurology 2005;62(4):653-8.
9.
Abe M, Fukudome K, Sugita Y, Oishi T, Tabuchi K, Kawano T. Thrombus and
encapsulated hematoma in cerebral cavernous malformations. Acta neuropathologica
2005; 109(5):503-9.
10.
Baev NI, Awad IA. Endothelial cell culture from human cerebral cavernous
malformations. Stroke; a journal of cerebral circulation 1998;29(11):2426-34.
11.
Robinson JR, Jr., Awad IA, Magdinec M, Paranandi L. Factors predisposing to
clinical disability in patients with cavernous malformations of the brain. Neurosurgery
1993;32(5):730-5; discussion 5-6.
12.
Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma.
Journal of neurosurgery 1991 ;75(5):709-14.
13.
Gault J, Shenkar R, Recksiek P, Awad IA. Biallelic somatic and germ line CCMl
truncating mutations in a cerebral cavernous malformation lesion. Stroke; a journal of
cerebral circulation 2005;36(4):872-4.
14.
Otten P, Pizzolato GP, Rilliet B, Berney J. [131 cases of cavernous angioma
(cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies].
Neuro-Chirurgie 1989;35(2):82-3, 128-31.
15.
Alberts MJ. Stroke genetics update. Stroke; a journal of cerebral circulation
2003;34(2):342-4.
16.
Winkler D, Lindner D, Trantakis C, et al. Cavernous malformations--navigational
supported surgery. Minim Invasive Neurosurg 2004;47(1):24-8.
17.
Macdonald RL. Advances in vascular surgery. Stroke; a journal of cerebral
circulation 2004;35(2):375-80.

ii
18.
Anderson RC, Connolly ES, Jr., Ozduman K, et al. Clinicopathological review:
giant intraventricular cavernous malformation. Neurosurgery 2003;53(2):374-8;
discussion 8-9.
19.
Laurans MS, DiLuna ML, Shin D, et al. Mutational analysis of 206 families with
cavernous malformations. Journal of neurosurgery 2003;99(1):38-43.
20.
Fustinoni 0, Biller J. Ethnicity and stroke: beware of the fallacies. Stroke; a
journal of cerebral circulation 2000;31(5): 1013-5.
21.
Alberts MJ. Genetics update: impact of the human genome projects and
identification of a stroke gene. Stroke; a journal of cerebral circulation 2001;32(6): 123941.
22.
Craig HD, Gunel M, Cepeda 0, et al. Multilocus linkage identifies two new loci
for a mendelian form of stroke, cerebral cavernous malformation, at 7pI5-13 and 3q25.227. Human molecular genetics 1998;7(12):1851-8.
23.
Gunel M, Lifton RP. Counting strokes. Nature genetics 1996;13(4):384-5.
24.
Gunel M, Laurans MS, Shin D, et al. KRITl, a gene mutated in cerebral
cavernous malformation, encodes a microtubule-associated protein. Proceedings of the
National Academy of Sciences of the United States of America 2002;99(16): 10677-82.
25.
Gault J, Sain S, Hu LJ, Awad IA. Spectrum of genotype and clinical
manifestations in cerebral cavernous malformations. Neurosurgery 2006;59(6): 1278-84;
discussion 84-5.
26.
Alberts MJ, Tournier-Lasserve E. Update on the genetics of stroke and
cerebrovascular disease 2004. Stroke; ajournal of cerebral circulation 2005;36(2):17981.
27.
Serebriiskii I, Estojak J, Sonoda G, Testa JR, Golemis EA. Association of Krevl/rapla with Kritl, a novel ankyrin repeat-containing protein encoded by a gene mapping
to 7q21-22. Oncogene 1997;15(9):1043-9.
28.
Pizon V, Chardin P, Lerosey I, Olofsson B, Tavitian A. Human cDNAs rap 1 and
rap2 homologous to the Drosophila gene Dras3 encode proteins closely related to ras in
the 'effector' region. Oncogene 1988;3(2):201-4.
29.
Henkemeyer M, Rossi DJ, Holmyard DP, et al. Vascular system defects and
neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature
1995;377(6551):695-701.
30.
Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Brafdeficient mice. Nature genetics 1997;16(3):293-7.
31.
Bos JL. All in the family? New insights and questions regarding interconnectivity
of Ras, Rapl and Ral. The EMBO journal 1998;17(23):6776-82.
32.
Laberge-Ie Couteulx S, Jung HH, Labauge P, et al. Truncating mutations in
CCMl, encoding KRITl, cause hereditary cavernous angiomas. Nature genetics
1999;23(2): 189-93.
33.
Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk
DA. Loss of p53 sensitizes mice with a mutation in Ccrnl (KRITl) to development of
cerebral vascular malformations. The American journal of pathology 2004; 165(5): 150918.
34.
Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY. Ccml is required
for arterial morphogenesis: implications for the etiology of human cavernous
malformations. Development (Cambridge, England) 2004; 131(6): 1437-48.

III

35.
Guzeloglu-Kayisli 0, Amankulor NM, Voorhees J, Luleci G, Lifton RP, Gunel
M. KRITlIcerebral cavernous malformation 1 protein localizes to vascular endothelium,
astrocytes, and pyramidal cells of the adult human cerebral cortex. Neurosurgery
2004;54(4):943-9; discussion 9.
36.
Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA. KRITI
association with the integrin-binding protein ICAP-I: a new direction in the elucidation
of cerebral cavernous malformations (CCMI) pathogenesis. Human molecular genetics
2002;11(4):389-96.
37.
Zhang J, Clatterbuck RE, Rigamonti D, Chang DD, Dietz HC. Interaction
between kritland icap 1alpha infers perturbation of integrin betal-mediated angiogenesis
in the pathogenesis of cerebral cavernous malformation. Human molecular genetics
2001; 10(25):2953-60.
38.
Gunel M, Awad IA, Finberg K, et al. Genetic heterogeneity of inherited cerebral
cavernous malformation. Neurosurgery 1996;38(6): 1265-71.
39.
Liquori CL, Berg MJ, Squitieri F, et al. Deletions in CCM2 are a common cause
of cerebral cavernous malformations. American journal of human genetics
2007;80(1):69-75.
40.
Seker A, Pricola KL, Guclu B, Ozturk AK, Louvi A, Gunel M. CCM2 expression
parallels that of CCM1. Stroke; a journal of cerebral circulation 2006;37(2):518-23.
41.
Zawistowski JS, Stalheim L, Uhlik MT, et al. CCMI and CCM2 protein
interactions in cell signaling: implications for cerebral cavernous malformations
pathogenesis. Human molecular genetics 2005;14(17):2521-31.
42.
Busch CR, Heath DD, Hubberstey A. Sensitive genetic biomarkers for
determining apoptosis in the brown bullhead (Ameiurus nebulosus). Gene 2004;329:1-10.
43.
Bergametti F, Denier C, Labauge P, et al. Mutations within the programmed cell
death 10 gene cause cerebral cavernous malformations. American journal of human
genetics 2005;76(1):42-51.
44.
Denier C, Labauge P, Bergametti F, et al. Genotype-phenotype correlations in
cerebral cavernous malformations patients. Annals of neurology 2006;60(5):550-6.
45.
Gunel M, Awad IA, Finberg K, et al. A founder mutation as a cause of cerebral
cavernous malformation in Hispanic Americans. The New England journal of medicine
1996;334( 15):946-51.
46.
Dubovsky J, Zabramski JM, Kurth J, et al. A gene responsible for cavernous
malformations of the brain maps to chromosome 7q. Human molecular genetics
1995;4(3):453-8.
47.
Capo-Aponte JE, Wang Z, Bildin VN, Pokorny KS, Reinach PS. Fate of
hypertonicity-stressed corneal epithelial cells depends on differential MAPK activation
and p38MAPKlNa-K-2CI cotransporterl interaction. Experimental eye research
2007;84(2):361-72.
48.
Miyagawa J, Muguruma M, Aoto H, Suetake I, Nakamura M, Tajima S. Isolation
of the novel cDNA of a gene of which expression is induced by a demethylating stimulus.
Gene 1999;240(2):289-95.
49.
Vallim MA, Nichols CB, Fernandes L, Cramer KL, Alspaugh JA. A Rac homolog
functions downstream of Ras 1 to control hyphal differentiation and high-temperature
growth in the pathogenic fungus Cryptococcus neoformans. Eukaryotic cell
2005;4(6): 1066-78.

IV

50.
Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation.
Oncogene 2004;23(16):2838-49.
51.
Murray U , Abrams TJ, Long KR, et al. SU1l248 inhibits tumor growth and CSFlR-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical
& experimental metastasis 2003;20(8):757-66.
52.
Mavria G, Vercoulen Y, Yeo M, et al. ERK-MAPK signaling opposes Rho-kinase
to promote endothelial cell survival and sprouting during angiogenesis. Cancer cell
2006;9(1):33-44.
53.
Yang CH, Murti A, Pfeffer LM. Interferon induces NF-kappa B-inducing
kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation
to promote cell survival. The Journal of biological chemistry 2005;280(36):31530-6.
54.
Huangfu WC, Omori E, Akira S, Matsumoto K, Ninomiya-Tsuji J. Osmotic stress
activates the TAKI-JNK pathway while blocking TAK1-mediated NF-kappaB activation:
TA02 regulates TAKI pathways. The Journal of biological chemistry
2006;281(39):28802-10.
55.
Kim JH, Lee HK, Takamiya K, Huganir RL. The role of synaptic GTPaseactivating protein in neuronal development and synaptic plasticity. J Neurosci
2003;23(4): 1119-24.
56.
Wajant H, Grell M, Scheurich P. TNF receptor associated factors in cytokine
signaling. Cytokine & growth factor reviews 1999;10(1):15-26.
57. ' Wajant H, Muhlenbeck F, Scheurich P. Identification of a TRAF (TNF receptorassociated factor) gene in Caenorhabditis elegans. Journal of molecular evolution
1998;47(6):656-62.
58.
Huang CJ, Chen CY, Chen HH, Tsai SF, Choo KB. TDPOZ, a family of bipartite
animal and plant proteins that contain the TRAF (TD) and POZIBTB domains. Gene
2004;324: 117-27.
59.
Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide
activates nuclear factor-kappaB through interleukin-I signaling mediators in cultured
human dermal endothelial cells and mononuclear phagocytes. The Journal of biological
chemistry 1999;274(12):7611-4.
60.
Majumdar S, Aggarwal BB. Adenosine suppresses activation of nuclear factorkappaB selectively induced by tumor necrosis factor in different cell types. Oncogene
2003;22(8): 1206-18.
61.
Lotocki G, Alonso OF, Dietrich WD, Keane RW. Tumor necrosis factor receptor
1 and its signaling intermediates are recruited to lipid rafts in the traumatized brain. J
Neurosci 2004;24(49): 11010-6.
62.
Yang CH, Murti A, Valentine WJ, Du Z, Pfeffer LM. Interferon alpha activates
NF-kappaB in JAKI-deficient cells through a TYK2-dependent pathway. The Journal of
biological chemistry 2005;280(27):25849-53.
63.
Shi CS, Leonardi A, Kyriakis J, Siebenlist U, Kehrl JH. TNF-mediated activation
of the stress-activated protein kinase pathway: TNF receptor-associated factor 2 recruits
and activates germinal2enter kinase related. J Immunol 1999;163(6):3279-85.
64.
Brink R, Lodish HF. Tumor necrosis factor receptor (TNFR)-associated factor 2A
(TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits
TNFR2-mediated NF-kappaB activation. The Journal of biological chemistry
1998;273(7):4129-34.

v
65.
Lee ZH, Lee SE, Kwack K, et al. Caspase-mediated cleavage ofTRAF3 in FasLstimulated Jurkat-T cells. Journal ofleukocyte biology 2001;69(3):490-6.
66.
Masson R, Regnier CH, Chenard MP, et al. Tumor necrosis factor receptor
associated factor 4 (TRAF4) expression pattern during mouse development. Mechanisms
of development 1998;71(1-2):187-91.
67.
Glauner H, Siegmund D, Motejadded H, et al. Intracellular localization and
transcriptional regulation of tumor necrosis factor (TNF) receptor-associated factor 4
(TRAF4). European journal of biochemistry / FEBS 2002;269(19):4819-29.
68.
Ishida T, Mizushima S, Azuma S, et al. Identification of TRAF6, a novel tumor
necrosis factor receptor-associated factor protein that mediates signaling from an aminoterminal domain of the CD40 cytoplasmic region. The Journal of biological chemistry
1996;271(46):28745-8.
69.
Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial
lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of
NF-kappaB and c-Jun N-terminal kinase. Blood 2003; 102(5): 1740-2.
70.
Wong F, Hull C, Zhande R, Law J, Karsan A. Lipopolysaccharide initiates a
TRAF6-mediated endothelial survival signal. Blood 2004; 103(12):4520-6.
71.
Dan I, Watanabe NM, Kusumi A. The Ste20 group kinases as regulators of MAP
kinase cascades. Trends in cell biology 2001;11(5):220-30.
72.
Raitt DC, Posas F, Saito H. Yeast Cdc42 GTPase and Ste20 PAK-like kinase
regulate Sho I-dependent activation of the Hogl MAPK pathway. The EMBO journal
2000;19(17):4623-31.
73.
Tassi E, Biesova Z, Di Fiore PP, Gutkind JS, Wong WT. Human JIK, a novel
member of the STE20 kinase family that inhibits JNK and is negatively regulated by
epidermal growth factor. The Journal of biological chemistry 1999;274(47):33287-95.
74.
Strange K, Denton J, Nehrke K. Ste20-type kinases: evolutionarily conserved
regulators of ion transport and cell volume. Physiology (Bethesda, Md 2006;21:61-8.
75.
Huang CY, Wu YM, Hsu CY, et al. Caspase activation of mammalian sterile 20like kinase 3 (Mst3). Nuclear translocation and induction of apoptosis. The Journal of
biological chemistry 2002;277(37):34367-74.
76.
Madhani RD. Functional analysis of protein kinase networks in living cells:
beyond "knock-outs" and "knock-downs". Methods (San Diego, Calif 2006;40(3):251-4.
77.
Kritikou EA, Milstein S, Vidalain PO, et al. C. elegans GLA-3 is a novel
component of the MAP kinase MPK-l signaling pathway required for germ cell survival.
Genes & development 2006;20(16):2279-92.
78.
Shao D, Zheng W, Qiu W, Ouyang Q, Tang C. Dynamic studies of scaffolddependent mating pathway in yeast. Biophysical journal 2006;91(11):3986-4001.
79.
Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods (San
Diego, Calif 1998;14(4):381-92.
80.
Perkins AS. Functional genomics in the mouse. Functional & integrative
genomics 2002;2(3):81-91.
.
81.
McDermott EP, O'Neill LA. Ras participates in the activation of p38 MAPK by
interleukin-l by associating with IRAK, IRAK2, TRAF6, and TAK-1. The Journal of
biological chemistry 2002;277(10):7808-15.

VI

82.
Sahoo T, Johnson EW, Thomas JW, et al. Mutations in the gene encoding KRIT1,
a Krev-lIrapla binding protein, cause cerebral cavernous malformations (CCM1).
Human molecular genetics 1999;8(12):2325-33.
83.
Uhlik MT, Abell AN, Johnson NL, et aI. Rac-MEKK3-MKK3 scaffolding for p38
MAPK activation during hyperosmotic shock. Nature cell biology 2003;5(12): 1104-10.
84.
Bix G, Fu J, Gonzalez EM, et aI. Endorepellin causes endothelial cell disassembly
of actin cytoskeleton and focal adhesions through alpha2betal integrin. The Journal of
cell biology 2004;166(1):97-109.
85.
Mainiero F, Colombara M, Antonini V, et al. p38 MAPK is a critical regulator of
the constitutive and the beta4 integrin-regulated expression of IL-6 in human normal
thymic epithelial cells. European journal of immunology 2003;33(11):3038-48.
86.
Schliess F, Reissmann R, Reinehr R, vom Dahl S, Haussinger D. Involvement of
integrins and Src in insulin signaling toward autophagic proteolysis in rat liver. The
Journal of biological chemistry 2004;279(20):21294-301.
87.
Sweeney SM, DiLullo G, Slater SJ, et al. Angiogenesis in collagen I requires
alpha2betalligation of a GFP*GER sequence and possibly p38 MAPK activation and
focal adhesion disassembly. The Journal of biological chemistry 2003;278(33):30516-24.
88.
Wernig F, Mayr M, Xu Q. Mechanical stretch-induced apoptosis in smooth
muscle cells is mediated by betal-integrin signaling pathways. Hypertension
2003;41(4):903-11.
89.
Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement
for p38alpha in erythropoietin expression : a role for stress kinases in erythropoiesis. Cell
2000; 102(2):221-31.
90.
Falsig J, Latta M, Leist M. Defined inflammatory states in astrocyte cultures:
correlation with susceptibility towards CD95-driven apoptosis. Journal of neurochemistry
2004;88(1): 181-93.
91.
Attisano L, Labbe E. TGFbeta and Wnt pathway cross-talk. Cancer metastasis
reviews 2004;23(1-2):53-61.
92.
Ross RS. Molecular and mechanical synergy: cross-talk between integrins and
growth factor receptors. Cardiovascular research 2004;63(3):381-90.
93.
Surmacz E, Bartucci M. Role of estrogen receptor alpha in modulating IGF-I
receptor signaling and function in breast cancer. J Exp Clin Cancer Res 2004;23(3):38594.
94.
Hynes RO, Lively JC, McCarty JH, et aI. The diverse roles of integrins and their
ligands in angiogenesis. Cold Spring Harbor symposia on quantitative biology
2002;67: 143-53.
95.
Chang DD, Wong C, Smith H, Liu J. ICAP-I, a novel beta I integrin cytoplasmic
domain-associated protein, binds to a conserved and functionally important NPXY
sequence motif of beta I integrin. The Journal of cell biology 1997;138(5): 1149-57.
96.
Bouvard D, Vignoud L, Dupe-Manet S, et al. Disruption of focal adhesions by
integrin cytoplasmic domain-associated protein-I alpha. The Journal of biological
chemistry 2003;278(8):6567-74.
97.
Retta SF, Avolio M, Francalanci F, et aI. Identification of KritlB: a novel
alternati ve splicing isoform of cerebral cavernous malformation gene-I. Gene
2004;325:63-78.

Vll

98.
Vranishi R, Baev NI, Kim JH, Awad lA. Vascular smooth muscle cell
differentiation in human cerebral vascular malformations. Neurosurgery 2001;49(3):6719; discussion 9-80.
99.
Guzeloglu-Kayisli 0, Kayisli VA, Amankulor NM, et al. Krevl interaction
trapped-llcerebral cavernous malformation-l protein expression during early
angiogenesis. Journal of neurosurgery 2004; 100(5 Suppl Pediatrics):481-7.
100. Cambier S, Gline S, Mu D, et al. Integrin alpha(v)beta8-mediated activation of
transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch.
The American journal of pathology 2005;166(6): 1883-94.
101. McCarty JH, Lacy-Hulbert A, Charest A, et al. Selective ablation of alphav
integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal
degeneration and premature death. Development (Cambridge, England) 2005;132(1):16576.
102. McCarty JH, Monahan-Earley RA, Brown LF, et al. Defective associations
between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking
alphav integrins. Molecular and cellular biology 2002;22(21):7667-77.
103. Ma X, Zhao H, Shan J, et al. PDCDIO Interacts with Ste20-related Kinase MST4
to Promote Cell Growth and Transformation via Modulation of ERK Pathway. Mol Bioi
Cell 2007.
104. Clatterbuck RE, Cohen B, Gailloud P, Murphy K, Rigamonti D. Vertebral
hemangiomas associated with familial cerebral cavernous malformation: segmental
disease expression. Case report. Journal of neurosurgery 2002;97(2 Suppl):227-30.
105. Robinson JR, Jr., Awad lA, Zhou P, Barna BP, Estes ML. Expression of basement
membrane and endothelial cell adhesion molecules in vascular malformations of the
brain: preliminary observations and working hypothesis. Neurological research
1995;17(1):49-58.
106. Hao W, Takano T, Guillemette J, Papillon J, Ren G, Cybulsky AV. Induction of
apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis
signal-regulating kinase and p38. The Journal of biological chemistry 2006;281(6):307584.

